CGTLive’s Weekly Rewind – May 13, 2022
Review top news and interview highlights from the week ending May 13, 2022.
Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
1. Caribou’s CRISPR-Edited CAR T-Cell Therapy CB-010 Elicits Complete Response in R/R B-NHL
Caribou will present the initial data at the upcoming European Hematology Association (EHA) meeting in June.
2. REGENXBIO DMD Gene Therapy Trial Delayed Due to Manufacturing Issue
The trial was set to begin patient dosing in the first half of this year.
3. Arcellx Doses First Patient in ARC-SparX CAR-T Program for Multiple Myeloma
The cell therapy is the first to come out of the company’s proprietary ARC-SparX platform.
4. Takeaways From Phase 1 Trial of RTX-240 in Solid Tumors: Alexander I. Spira, MD, PhD, FACP
Alexander I. Spira, MD, PhD, FACP, research institute director with Virginia Cancer Specialists Research Institute, discusses the examination of RTX-240 in a phase 1 trial with solid tumors, presented recently at the 2022 AACR Annual Meeting.
5. Gene Therapy for Overactive Bladder, Incontinence Shows Good Safety, Efficacy
The locally injected gene therapy product is the subject of an ongoing phase 2a clinical trial.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Jeffrey Chamberlain, PhD, on the Import of Early Intervention in DMD
July 10th 2025The McCaw Endowed Chair of Muscular Dystrophy at University of Washington, discussed how comprehensive care for DMD patients involves early diagnosis, steroid treatment, consideration of mutation-specific therapies, and more.
